BiotechTube

Sutent®/Sunitinib

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis

Conditions

Neurofibromatosis, NF1, Plexiform Neurofibromas

Trial Timeline

Mar 1, 2012 → Feb 14, 2018

NCT ID
NCT01402817

About Sutent®/Sunitinib

Sutent®/Sunitinib is a phase 2 stage product being developed by Pfizer for Neurofibromatosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01402817. Target conditions include Neurofibromatosis, NF1, Plexiform Neurofibromas.

What happened to similar drugs?

0 of 1 similar drugs in Neurofibromatosis were approved

Approved (0) Terminated (0) Active (1)
🔄SelumetinibAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01402817Phase 2Terminated

Competing Products

20 competing products in Neurofibromatosis

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
27
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
29
AZD2014AstraZenecaPhase 2
35
Selumetinib + PlaceboAstraZenecaPhase 2
27
Treatment A + Treatment B + Treatment C + Treatment D + AcetaminophenAstraZenecaPhase 1
29
SelumetinibAstraZenecaPhase 1/2
32
SelumetinibAstraZenecaPhase 1
33
Selumetinib granule formulation + Selumetinib capsule formulationAstraZenecaPhase 1/2
36
SelumetinibAstraZenecaPhase 3
44
Everolimus (RAD001) , Afinitor®NovartisPhase 2
35
RAD001: EverolimusNovartisPhase 2
35
RAD001, everolimusNovartisPhase 2
27
TasignaNovartisPhase 1
29
TrametinibNovartisPhase 2
39
Everolimus (RAD001)NovartisPhase 2
27
Sorafenib (Nexavar)BayerPhase 2
24
PTC299United TherapeuticsPhase 2
24
REC-2282 + PlaceboRecursion PharmaceuticalsPhase 2/3
24
BinimetinibPacific BiosciencesPhase 2
25